IT201900021327A1 - Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori. - Google Patents

Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori.

Info

Publication number
IT201900021327A1
IT201900021327A1 IT102019000021327A IT201900021327A IT201900021327A1 IT 201900021327 A1 IT201900021327 A1 IT 201900021327A1 IT 102019000021327 A IT102019000021327 A IT 102019000021327A IT 201900021327 A IT201900021327 A IT 201900021327A IT 201900021327 A1 IT201900021327 A1 IT 201900021327A1
Authority
IT
Italy
Prior art keywords
tumors
antisense oligonucleotide
oligonucleotide sequences
met transcript
silence human
Prior art date
Application number
IT102019000021327A
Other languages
English (en)
Inventor
Tiziana Venesio
Original Assignee
Fond Del Piemonte Per Loncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Del Piemonte Per Loncologia filed Critical Fond Del Piemonte Per Loncologia
Priority to IT102019000021327A priority Critical patent/IT201900021327A1/it
Priority to JP2022525621A priority patent/JP2023502330A/ja
Priority to CN202080079454.6A priority patent/CN114729364A/zh
Priority to PCT/IT2020/050282 priority patent/WO2021095080A1/en
Priority to CA3161155A priority patent/CA3161155A1/en
Priority to AU2020381988A priority patent/AU2020381988A1/en
Priority to EP20811762.2A priority patent/EP4058576A1/en
Priority to US17/776,399 priority patent/US20220411803A1/en
Publication of IT201900021327A1 publication Critical patent/IT201900021327A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT102019000021327A 2019-11-15 2019-11-15 Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori. IT201900021327A1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT102019000021327A IT201900021327A1 (it) 2019-11-15 2019-11-15 Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori.
JP2022525621A JP2023502330A (ja) 2019-11-15 2020-11-13 腫瘍におけるヒトｌ１－ｍｅｔ転写産物をサイレンシングするためのアンチセンスオリゴヌクレオチド配列
CN202080079454.6A CN114729364A (zh) 2019-11-15 2020-11-13 用于沉默肿瘤中的人l1-met转录物的反义寡核苷酸序列
PCT/IT2020/050282 WO2021095080A1 (en) 2019-11-15 2020-11-13 Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours
CA3161155A CA3161155A1 (en) 2019-11-15 2020-11-13 Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours
AU2020381988A AU2020381988A1 (en) 2019-11-15 2020-11-13 Antisense oligonucleotide sequences for silencing the human L1-MET transcript in tumours
EP20811762.2A EP4058576A1 (en) 2019-11-15 2020-11-13 Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours
US17/776,399 US20220411803A1 (en) 2019-11-15 2020-11-13 Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000021327A IT201900021327A1 (it) 2019-11-15 2019-11-15 Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori.

Publications (1)

Publication Number Publication Date
IT201900021327A1 true IT201900021327A1 (it) 2021-05-15

Family

ID=69811792

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000021327A IT201900021327A1 (it) 2019-11-15 2019-11-15 Sequenze di oligonucleotidi antisenso per silenziare il trascritto L1-MET umano nei tumori.

Country Status (8)

Country Link
US (1) US20220411803A1 (it)
EP (1) EP4058576A1 (it)
JP (1) JP2023502330A (it)
CN (1) CN114729364A (it)
AU (1) AU2020381988A1 (it)
CA (1) CA3161155A1 (it)
IT (1) IT201900021327A1 (it)
WO (1) WO2021095080A1 (it)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605259QA (en) * 2013-12-30 2016-07-28 Agency Science Tech & Res Methods for measuring biomarkers in gastrointestinal cancer

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BECK, C.R. ET AL.: "LINE-1 retrotransposition activity in human genomes", CELL, vol. 141, no. 7, 2010, pages 1159 - 70
BERRINO E. ET AL., CANCER RESEARCH, vol. 79, no. 13, Suppl. S, July 2019 (2019-07-01), ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); ATLANTA, GA, USA; MARCH 29 -APRIL 03, 2019, pages 261, XP055711944, DOI: 10.1158/1538-7445.AM2019-261 *
BO, X. ET AL.: "Selection of antisense oligonucleotides based on multiple predicted target mRNA structures", BMC BIOINFORMATICS, vol. 7, 2006, pages 122, XP021013625, DOI: 10.1186/1471-2105-7-122
BROUHA, B. ET AL.: "Hot L1s account for the bulk of retrotransposition in the human population", PROC NATL ACAD SCI U S A, vol. 100, no. 9, 2003, pages 5280 - 5, XP002382754, DOI: 10.1073/pnas.0831042100
CROOKE, S.T.: "Molecular Mechanisms of Antisense Oligonucleotides", NUCLEIC ACID THER, vol. 27, no. 2, 2017, pages 70 - 77
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 2019 (2019-07-01), BERRINO ENRICO ET AL.: "L1-MET transcription silencing modulates MET and EGFR gene and their protein expression and induces apoptosis and cell-death in different types of cancer cells", XP055711945, Database accession no. PREV202000077304 *
DENLI, A.M. ET AL.: "Primate-specific ORFO contributes to retrotransposon-mediated diversity", CELL, vol. 163, no. 3, 2015, pages 583 - 93, XP055651566, DOI: 10.1016/j.cell.2015.09.025
DI FUSCO, D. ET AL.: "Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease", FRONT PHARMACOL, vol. 10, 2019, pages 305
DOBIN, A. ET AL.: "STAR: ultrafast universal RNA-seq aligner", BIOINFORMATICS, vol. 29, no. 1, 2013, pages 15 - 21, XP055500895, DOI: 10.1093/bioinformatics/bts635
FRANKISH, A. ET AL.: "GENCODE reference annotation for the human and mouse genomes", NUCLEIC ACIDS RES, vol. 47, no. D1, 2019, pages D766 - D773
LIAO, Y.G.K. SMYTHW. SHI: "featureCounts: an efficient general purpose program for assigning sequence reads to genomic features", BIOINFORMATICS, vol. 30, no. 7, 2014, pages 923 - 30
MIGLIO, U. ET AL.: "The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers", INT J CANCER, vol. 143, no. 11, 2018, pages 2838 - 2848
NIGUMANN, P.K. REDIKK. MATLIKM. SPEEK: "Many human genes are transcribed from the antisense promoter of L1 retrotransposon", GENOMICS, vol. 79, no. 5, 2002, pages 628 - 34, XP004465134, DOI: 10.1006/geno.2002.6758
SHAO, Y.Y. WUC.Y. CHANK. MCDONOUGHY. DING: "Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation", NUCLEIC ACIDS RES, vol. 34, no. 19, 2006, pages 5660 - 9, XP055627587, DOI: 10.1093/nar/gkl715
SHEN, X.D.R. COREY: "Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs", NUCLEIC ACIDS RES, vol. 46, no. 4, 2018, pages 1584 - 1600
SPEEK, M.: "Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes", MOL CELL BIOL, vol. 21, no. 6, 2001, pages 1973 - 85
SWERGOLD, G.D.: "Identification, characterization, and cell specificity of a human LINE-1 promoter", MOL CELL BIOL, vol. 10, no. 12, 1990, pages 6718 - 29
WEBER, B.S. KIMHIG. HOWARDA. EDENF. LYKO: "Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription", ONCOGENE, vol. 29, no. 43, 2010, pages 5775 - 84
WOLFF, E.M. ET AL.: "Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer", PLOS GENET, vol. 6, no. 4, 2010, pages e1000917, XP055324148, DOI: 10.1371/journal.pgen.1000917

Also Published As

Publication number Publication date
JP2023502330A (ja) 2023-01-24
EP4058576A1 (en) 2022-09-21
US20220411803A1 (en) 2022-12-29
WO2021095080A1 (en) 2021-05-20
CA3161155A1 (en) 2021-05-20
CN114729364A (zh) 2022-07-08
AU2020381988A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CY1120495T1 (el) Ολιγονουκλεοτιδικα anaλoγα που στοχευουν το ανθρωπινο lmna
EA201892467A1 (ru) Олигонуклеотидные аналоги, нацеленные на lmna человека
WO2017062862A8 (en) Oligonucleotide compositions and methods thereof
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
PH12019501959A1 (en) Therapeutic rna
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
NZ724277A (en) Compositions and methods for modulating pkk expression
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
EA201790802A1 (ru) Соединения против tnf
IL275996A (en) Treatment using cytokine-encoded RNA
SG11201710312SA (en) Modified cyanide-free gold plating solution and use thereof, as well as preparation method for hard gold
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
WO2017055611A3 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2011019815A3 (en) Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
SG11202006528XA (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
ZA201902079B (en) Combination therapy with liposomal antisense oligonucleotides
MX2018006527A (es) Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer.
IL275902A (en) Antisense oligonucleotides directed against alpha-synculin and their uses
EP4175654A4 (en) ANTISENSE OLIGONUCLEOTIDES TARGETING SARS-COV-2
IL304679A (en) Antiretroviral oligonucleotides that increase foxg1 expression
IL309445A (en) PIKFYVE antisense oligonucleotides